Novavax, Inc. (NVAX) vs Trevi Therapeutics, Inc. (TRVI)
- Novavax, Inc. NVAX 10.00 −9.17%
- Trevi Therapeutics, Inc. TRVI 12.90 +1.02%
Novavax, Inc. and Trevi Therapeutics, Inc. are both Biotechnology companies. Novavax, Inc. and Trevi Therapeutics, Inc. are of similar size ($1.8B and $1.8B). Trevi Therapeutics, Inc. has the higher net margin (0.00% vs −59.9%) and the lower return on invested capital (−1,412.1% vs 0.00%). Across the 13 metrics below, Trevi Therapeutics, Inc. leads on 7 and Novavax, Inc. on 6.
Valuation
Profitability
| Metric | NVAX | TRVI | Biotechnology median |
|---|---|---|---|
| Gross margin | 78.60% | 0.00% | 65.77% |
| Operating margin | (56.58%) | 0.00% | 0.00% |
| Net margin | (59.87%) | 0.00% | 0.00% |
| Free cash flow margin | (10.20%) | 0.00% | 0.00% |
| Return on equity | 323.66% | (19.66%) | (54.09%) |
| Return on assets | (21.62%) | (18.97%) | (47.78%) |
| Return on invested capital | 0.00% | (1,412.11%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack